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Background and Objectives
This study explored variations in the clinical manifestations of intravascular lym-
phoma (IVL) on the bases of the association with hemophagocytosis and the country
where the diagnosis was made. 
Design and Methods
The clinical features of 50 Western patients with IVL were compared with those of
123 patients with IVL diagnosed in Eastern countries (87 diagnosed in Japan and 36
in other Asian countries), previously reported in English literature, and collected by an
electronic bibliographic search. 
Results
Hemophagocytosis was absent in Western patients, but reported in 38 (44%)
Japanese patients (p=0.00001) and in seven (19%) patients from other Asian coun-
tries (p=0.002). No clinical differences were evident between patients with hemo-
phagocytosis-negative IVL diagnosed in Western countries, Japan and other Asian
Countries. Conversely, Japanese and non-Japanese patients with hemophagocytosis-
related IVL more frequently had stage IV disease, fever, hepato-splenic involvement,
marrow infiltration, dyspnea, anemia, and thrombocytopenia, and rarely exhibited
cutaneous or central nervous system involvement. Lymph node and peripheral blood
involvement was uncommon in all subgroups. In Western patients, anthracycline-
based chemotherapy was associated with a 52% remission rate, and a 2-year overall
survival of 46%. 
Interpretation and Conclusions
The clinical features of IVL vary according to the association with hemophagocytosis,
regardless of the country in which the diagnosis is made. Western, Japanese and
other Asian patients with hemophagocytosis-negative IVL display similar clinical char-
acteristics and should be considered as having classical IVL. Patients with hemo-
phagocytosis-related IVL show significantly different clinical features. Both forms have
a poor prognosis. Extensive molecular studies are needed to explore whether these
clinical differences might reflect discordant biological entities within IVL.
Key words: intravascular lymphoma, hemophagocytosis, cutaneous lymphoma,
brain lymphoma.
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Intravascular lymphoma (IVL) is a rare entity character-ized by exclusive or predominant growth of neoplasticcells within the lumen of blood vessels. This disorder
was recently recognized as a subtype of diffuse large B-
cell lymphoma by the World Health Organization (WHO)
Classification,1 although rare forms with a T-cell pheno-
type also occur.2 The understanding of IVL is very limited
considering that, with a few exceptions,3,4 literature on
this malignancy is almost exclusively represented by case
reports and small case series.5-7 IVL is considered to be a
rapidly aggressive and disseminated disease, usually
affecting elderly patients, and is associated with a poor
performance status (PS), B symptoms, anemia, and elevat-
ed serum lactate dehydrogenase (LDH) levels.4 However,
the clinical presentation, behavior and therapeutic out-
come are extremely variable; in particular, it has been sug-
gested that there are some differences in clinical and
histopathological characteristics between patients diag-
nosed in Asian and Western countries.3,4,8,9 A large
Japanese study concluded that IVL associated with hemo-
phagocytosis (HPC) is the equivalent of the Asian variant of
IVL.4 In Western patients, a cutaneous variant, with a favor-
able clinical behavior, has been described.4 However, a
comprehensive and detailed comparison between rela-
tively large series from Western and Eastern countries has
not previously been performed, and clinical and biological
differences among these cohorts of patients are still debat-
ed. The acknowledgement of the existence of different
clinical forms may have diagnostic, prognostic and thera-
peutic implications and constitutes the rationale for fur-
ther investigations into the mechanisms of lymphomage-
nesis, adhesion and dissemination.10 This paper reports a
comparison of presenting symptoms, clinical features,
behavior, and therapeutic management of the largest
series of patients with IVL diagnosed in Western countries
with three potentially different subgroups of previously
reported cases of IVL diagnosed in Asian countries, in
order to assess whether apparent clinical differences may
be driven by the geographical distribution of IVL patients. 
Design and Methods
Study group (Western-IVL series)
A questionnaire requesting information about patients’
characteristics, clinical presentation, diagnosis, staging,
sites of disease, laboratory findings, treatment, objective
response, site and date of relapse, second line treatment,
survival, salient morphologic features, and autopsy find-
ings was sent to each participating center of the
International Extranodal Lymphoma Study Group
(I.E.L.S.G.). Criteria for including patients were a histolog-
ical diagnosis of IVL and no evidence of human immun-
odeficiency (HIV-1) infection or other immunodeficiency.
Thirty centers from ten countries provided retrospective-
ly collected, clinical and pathological data on 50 HIV-neg-
ative patients with an in vivo (n=38) or post-mortem (n=12)
histological diagnosis of IVL (from 1985 to 2006), which
constituted the Western-IVL series. Preliminary data of a
part of this series have been reported previously.4
Eastern cases 
Features of the Western-IVL series were compared with
those of cases of IVL diagnosed in Eastern countries and
previously reported in English literature. An electronic
search of Medline, Current Contents and Pubmed, updat-
ed to March 2006, was performed, including as key words
intravascular lymphoma, intravascular lymphomatosis,
angiotropic lymphoma, angioendotheliomatosis, and hemo-
phagocytosis. Each full paper was reviewed and duplicate
reports describing the same patients were included just
once. We found 123 previously reported cases of IVL diag-
nosed in Japan (n=87) and other Asian countries (n=36)
[see references in the linked file]. These groups were
divided accordingly to the country in which the diagnosis
was made and to the presence of HPC, which was defined
by the morphologic recognition of an excess of mature
benign-looking histiocytes with phagocytosis of erythro-
blasts, granulocytes and platelets in histopathological
specimens. Therefore, three main comparator groups
were considered: 1) Japanese patients with IVL and HPC
(J-HPC), 2) Japanese patients with IVL but without HPC
(J-IVL), and 3) patients with IVL without HPC diagnosed
in Asian countries other than Japan (Eastern-IVL).
Additionally, a small subgroup of patients with IVL and
HPC diagnosed in Western and Asian countries other than
Japan and previously reported in English literature was
considered for analysis [see references in the linked file]. 
Statistical considerations 
The distributions of clinical variables among the sub-
groups of patients were assessed by Fisher’s exact test for
categorical variables. Survival curves were generated by
the Kaplan-Meier method. Overall survival (OS) was cal-
culated from the date of pathologic diagnosis to death or
to the last date of follow-up, while event-free survival
(EFS) was calculated from the first day of treatment to
relapse, progression or death, or to the last date of follow-
up. The impact of clinical and therapeutic variables on
survival was evaluated using the log-rank test. All the
probability values were two-sided, with an overall signif-
icance level of 0.05. Analyses were carried out using the
Statistica 4.0 statistical package for Windows (Statsoft Inc,
1993, Tulsa, OK 74104, USA). 
Results
Study Population
HPC was absent in the 50 Western-IVL cases, but was
reported in 38 (44%) of the 87 Japanese patients
(p=0.00001) and in seven of the 36 patients (19%) diag-
nosed in other Asian countries (p=0.002). Accordingly, the
three main groups against which to compare the Western-
A.J.M. Ferreri et al.
| 488 | haematologica/the hematology journal | 2007; 92(04)
IVL series consisted of 38 J-HPC patients, 49 J-IVL patients
and 29 Eastern-IVL patients. Additionally, a small sub-
group of patients with IVL and HPC diagnosed in Western
(n=5) and Asian countries other than Japan (n=7) and pre-
viously reported in English literature was considered for
analysis. 
Clinical presentation
Comparisons of the patients’ characteristics at diagno-
sis between the Western-IVL series and the three main
groups of Asian patients are summarized in Table 1. The
number of patients with an in vivo diagnosis was 38 (76%)
Western-IVL, 35 (92%) J-HPC, 36 (74%) J-IVL, and 16
(55%) Eastern-IVL. No significant differences in age and
gender were observed among the subgroups. 
The clinical presentation was heterogeneous in
Western-IVL patients, with a remarkable deterioration in
PS, with an ECOG score ≥2 in 32 cases (64%). PS was
rarely reported in Asian series, but the constant presence
of systemic symptoms and multi-organ involvement in
reported cases suggests that IVL is associated with a poor
PS also among Asian patients. As reported in Table 1, with
a few exceptions, no significant differences in clinical fea-
tures were observed among Western-IVL, J-IVL and
Eastern-IVL subgroups. Conversely, several significant dif-
ferences were observed between these three subgroups
and patients with J-HPC. Thirty Western-IVL patients
(60%) had systemic symptoms, mostly represented by
fever, which was present in 21 cases (42%), and associat-
ed with other B symptoms in 12 cases. Fever as well as
fatigue and jaundice were significantly more common
among J-HPC patients (Table 1). Significant differences in
terms of Ann Arbor stage of disease and sites of disease
were observed. A large majority of J-HPC patients had
stage IV disease, which was observed in 76-82% of cases
in the other subgroups (Table 1). The most common sites
of disease in the Western-IVL series, i.e., skin (38%) and
central nervous system (42%), were involved in a signifi-
cantly lower proportion of cases in J-HPC patients (3%
and 21%, respectively). In the J-IVL and Eastern-IVL sub-
groups, the percentages of involvement of skin and central
nervous system were similar to those observed in the
Western series (Table 1). Cutaneous lesions were the sole
pathologic finding in 12 (24%) Western cases; these
patients were considered as having a cutaneous variant of
IVL. The cutaneous variant was diagnosed in 0%, 6% and
0% of J-HPC (p=0.0004), J-IVL (p=0.01) and Eastern-IVL
(p=0.002) subgroups, respectively. Involvement of
hemolymphatic organs was significantly more common
in J-HPC cases: 66%, 77% and 74% of these patients
showed liver, spleen and marrow involvement, respec-
tively, which was present in 26%, 26% and 30% of
Western-IVL patients (p=0.0002, 0.00001 and 0.0001,
respectively). With the exception of slightly more com-
mon involvement of liver in Eastern-IVL patients, no sig-
nificant differences in the involvement of hemolymphatic
organs were observed among Western-IVL, J-IVL and
Eastern-IVL subgroups (Table 1). There were no signifi-
Table 1. Clinical features in our series (Western), in Japanese cases with (J-HPC) or without (J-IVL) hemophagocytosis and in patients
with IVL without hemophagocytosis from Eastern countries other than Japan (Eastern-IVL).
J-HPC J-IVL Eastern-IVL
Variable Western series series p# series p# series p#
Number of patients 50 38 49 29
Median age (range) 68 (34-90) 67 (44-78) NS 69 (13-82) NS 62 (34-81) NS
Male gender 23 (46%) 19 (50%) NS 24 (49%) NS 14 (48%) NS
Previous or concomitant cancer 9 (18%) 4 ( 11%) NS 2 (  4%) 0.02 2 (7%) NS
Stage IV 38 (76%) 37 (97%) 0.004 40 (82%) NS 23 (79%) NS
Fever 21 (42%) 33 ( 87%) 0.00001 23 (47%) NS 18 (62%) NS
Fatigue 11 (22%) 17 (45%) 0.03 8 (16%) NS 5 (17%) NS
Jaundice 0 (0%) 10 (26%) 0.0002 0 (  0%) NS 2 (7%) NS
Cutaneous lesions 19 (38%) 1 (  3%) 0.0001 12 (24%) NS 3/18 (17%)* NS
Neurological involvement 21 (42%) 8 (21%) 0.03 26 (53%) NS 10 (34%) NS
Hepatic involvement 13 (26%) 25 (66%) 0.0002 15 (31%) NS 14 (48%) 0.05
Splenic involvement 13 (26%) 29 (77%) 0.00001 10 (20%) NS 12 (41%) NS
Bone marrow involvement 15 (30%) 28 (74%) 0.0001 17 (35%) NS 11 (38%) NS
Lymphadenopathy 4 (8%) 2 (5%) NS 2 ( 4%) NS 5 (17%) NS
Peripheral blood involvement 2 (4%) 5 (13%) NS 0/26 (0%)* NS 0 (0%) NS
Pulmonary involvement 9 (18%) 14 (37%) 0.04 13 (27%) NS 7 (25%) NS
NS: not significant; NR: not reported; *Relationship between number of positive cases and number of assessed cases; #p values for comparisons between the Western series
and the other subgroups.
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cant differences in lymph-node and peripheral blood
involvement among the four studied subgroups, infiltra-
tion rates ranged between 4% and 17% and between 0%
and 13%, respectively (Table 1).
Histopathological and laboratory findings
In the 38 Western-IVL patients with an in vivo diagnosis,
the histopathological diagnosis was performed on tissue
samples obtained by partial surgical biopsy in 29 cases
(skin in 18 cases, central nervous system in five, lung in
two, uterus in two, gallbladder in one, and liver in one),
visceral resection in six (kidney in three, prostate in two
and spleen in one) and bone marrow biopsy in three
cases. By definition, all cases from the four subgroups
showed large lymphoid cells within vessel lumina (Figure
1). Lymphomatous lesions with infiltration of extravascu-
lar tissues (called extravascular component) were observed in
ten (20%) Western cases, and was significantly more com-
mon in samples from lung and kidney of J-HPC cases. All
Western-IVL cases but one displayed a B-cell immunophe-
notype. T-cell immunophenotype was observed in one
(2%) Western-IVL case, in one (3%) J-HPC case, in one J-
IVL (2%), and in five (17%) Eastern-IVL cases (p≤0.03
between Eastern-IVL cases and the other three groups; not
significant differences among the others). 
As reported in Table 2, no significant differences in lab-
oratory findings were noted among Western-IVL, J-IVL
and Eastern-IVL subgroups; while a different biochemical
profile was observed in J-HPC patients. In fact, anemia
(84%) and thrombocytopenia (74%) were significantly
more common in J-HPC cases than in the other three sub-
groups. Thrombocytopenia was associated with anemia,
bone marrow infiltration and hepato-splenic involvement
in each subgroup. Increased serum LDH  levels were
observed in all J-HPC patients and in 85%-94% of cases
in the other subgroups (Table 2). Increased levels of β2-
microglobulin and elevated erythrocyte sedimentation
rates were observed in, respectively, 84% and 48% of
Western-IVL cases, while these parameters were not
reported for patients in the other subgroups. A monoclon-
al serum component was reported in 5% - 16% of cases
in the studied subgroups (p= not significant). Elevated
transaminases and total bilirubin levels were significantly
more common among J-HPC cases than in the other sub-
groups (Table 2). 
Comparison with patients with HPC-related IVL 
diagnosed outside Japan
The Western-IVL series was also compared with the
small group (n=12) of patients with HPC-related IVL diag-
nosed in Western (n=5) or Eastern (n=7) countries other
than Japan and previously reported in English literature
Table 2. Laboratory findings in our series (Western), in Japanese cases with (J-HPC) or without (J-IVL) hemophagocytic features and in
IVL cases from Eastern countries other than Japan (Eastern-IVL). 
J-HPC J-IVL Eastern-IVL
Variable Western series series p# series p# series p#
Number of patients 50 38 49 29
Anemia 33 (66%) 32 (84%) 0.05 16/25 (64%)* NS 19 (66%) NS
Leukopenia 11 (22%) 11 (29%) NS 4/25 (16%)* NS 6 (21%) NS
Thrombocytopenia 16 (32%) 28 (74%) 0.0003 7/25 (28%)* NS 14 (48%) NS
High serum LDH levels 33/39 (85%)* 36/36 (100%)* 0.02 31/33 (94%)* NS 21/23 (91%)* NS
High β2-microglobulin 16/19 (84%)* NR NR NR
Elevated ESR 22/46 (48%)* NR NR NR
Monoclonal component 7/45 (16%)* 5 (13%) NS 1/20 ( 5%)* NS NR
High ALT levels 3 (  6%) 10 (26%) 0.02 3 (6%) NS 1/13 ( 8%)* NS
High bilirubin levels 1 (  2%) 11 (29%) 0.0008 0 (0%) NS 2 ( 7%) NS
NS: not significant; NR: not reported; LDH: lactate dehydrogenase; ESR: erythrocyte sedimentation rate; ALT: alanine amino transferase; *Relationship between
number of positive cases and number of assessed cases; #p values for comparisons between the Western series and the other subgroups.
Figure 1. Intravascular lymphoma of the cardiac muscle (hema-
toxylin and eosin). The growth of neoplastic large cells (arrows)
occurs within the lumen of blood vessels. Neoplastic lymphocytes
show large nuclei with one or more nucleoli and scant cytoplasm. 
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[see references in the linked file] to better understand whether
clinical features are related to HPC independently of the
country of origin of the patient. As reported in Table 3,
these patients exhibited similar characteristics to J-HPC
patients, while displaying many differences compared to
Western-IVL patients. Similarly to J-HPC patients,
patients with HPC-positive IVL diagnosed outside Japan
more commonly had stage IV disease, fever, thrombocy-
topenia, and involvement of liver, spleen and bone mar-
row. A higher prevalence of cutaneous lesions in non-
Japanese patients with HPC-positive IVL was the only
distinctive feature in comparison with J-HPC patients
(Table 3). 
Therapeutic outcome
In Western-IVL series, in vivo diagnosis was possible in
38 patients, 36 of whom received at least one line of treat-
ment. Seventeen (47%) achieved a complete remission
(CR) and four had a partial response (PR), for an overall
response rate of 58%; nine patients experienced progres-
sive disease (PD), two had stable disease, and four died of
toxicity. There were 23 treatment failures: 11 PD, eight
relapses after response and four toxic deaths, All treat-
ment failures but one occurred within the first year of fol-
low-up. Anthracycline-based chemotherapy was admin-
istered as initial treatment to 25 patients, resulting in a CR
rate of 52%, a median OS of 10+ months and a 2-year OS
of 46±10%. The median EFS for the 38 patients with an in
vivo diagnosis was 6 months (range 1-81), with a 2-year
EFS of 32±8%. Seventeen patients are alive at a median
follow-up of 28 months, with a 2-year OS of 39±8%.
Considering the entire series (including patients with a
post-mortem diagnosis), the 2-year EFS and OS were
24±6% and 30±7%, respectively. 
Discussion
The comparison of our series, the largest one of IVL
patients diagnosed in Western countries, with IVL cases
from Asian countries strongly suggests the existence of
different clinical forms of IVL. This issue does not seem
simply to reflect regional differences since IVL cases with
similar clinico-pathological characteristics have been
reported in Western countries, in Japan and in other
Asiatic countries (the Western-IVL, J-IVL and Eastern-IVL
groups in this study). Patients from these three subgroups
could be comprehensively considered as having the classi-
cal form of IVL. By contrast, patients with IVL associated
with HPC, who have been mostly reported in Japan (the
J-HPC group in this study), display clinical features dis-
tinct from those observed in the patients with the classical
form. Patients with IVL and HPC diagnosed in countries
other than Japan display similar characteristics to those of
J-HPC patients, while Japanese patients with IVL without
HPC (the J-IVL group) show similar features to those of
Western patients. Taken together, these data suggest that
differences in clinical presentation and behavior in IVL
Table 3. Clinical features and laboratory findings in patients with IVL and hemophagocytic features (HPC) diagnosed in Western or
Eastern countries other than Japan in comparison with our series (Western) and J-HPC patients 
Non-Japanese pts with IVL and HPC Western series J-HPC
Variable series p# series p#
Number of patients 12 50 38
Median age (range) 60 (54-77) 68 (34-90) NS 67 (44-78) NS
Male gender 6 (50%) 23 (46%) NS 19 (50%) NS
Stage IV 12 (100%) 38 (76%) 0.04 37 ( 97%) NS
Fever 11 (92%) 21 (42%) 0.002 33 ( 87%) NS
Jaundice 2 (17%) 0 (  0%) 0.008 10 (26%) NS
Cutaneous lesions 4 (33%) 19 (38%) NS 1 (  3%) 0.009
CNS involvement 2 (17%) 21 (42%) 0.02 8 (21%) NS
Hepatic involvement 7 (58%) 13 (26%) 0.03 25 (66%) NS
Splenic involvement 7 (58%) 13 (26%) 0.03 29 (77%) NS
Marrow involvement 9 (75%) 15 (30%) 0.007 28 (74%) NS
Lymphadenopathy 1 (8%) 4 (8%) NS 2 (5%) NS
Lung involvement 3 (35%) 9 (18%) NS 14 (37%) NS
Anemia 9 (75%) 33 (66%) NS 32 (84%) NS
Leukopenia 4 (33%) 11 (22%) NS 11 (29%) NS
Thrombocytopenia 10 (83%) 16 (32%) 0.003 28 (74%) NS
High serum LDH levels 11 (92%) 33/39 (85%)* NS 36/36 (100%)* NS
High ALT levels 5 (42%) 3 (6%) 0.006 10 (26%) NS
High bilirubin levels 5 (42%) 1 (2%) 0.0008 11 (29%) NS
NS: not significant; NR: not reported; CNS: central nervous system; PB: peripheral blood; LDH: lactate dehydrogenase; ESR: erythrocyte sedimentation rate; ALT: ala-
nine amino transferase; *Relationship between number of positive cases and number of assessed cases. #p values for comparisons between the group of patients with IVL
and HPC diagnosed in countries other than Japan and the other subgroups.
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might be more related to the concomitant presence of
HPC rather than the geographical distribution of the dis-
ease per se. 
This study is the first one comparing large series of IVL
patients diagnosed in different geographical regions. The
study of cumulative retrospective series and comparison
with previously reported cases is so far the only strategy
available for studying IVL given the extreme rarity of this
disease and the diagnostic difficulties. Conclusions from
this study should be viewed with caution, not only
because of the intrinsic caveats regarding the methods
used, but also considering that cases published in non-
English literature were not included in this analysis, which
may have introduced some interpretation biases.
Nevertheless, the size of the studied subgroups, the high
proportion of patients with an in vivo diagnosis and the
quality of reports in English literature support our conclu-
sions. Moreover, the clinical features observed in the J-
HPC and J-IVL subgroups have been confirmed by a
recently reported study including the largest series of
Japanese patients with IVL (n=96).11 Our observations
suggest that, unlike in Japanese patients,8 HPC is rarely
observed in IVL cases diagnosed in Western countries.
Among 321 cases of IVL diagnosed in Western countries,
and published in English literature, morphologically con-
firmed HPC has been reported in only five cases (1.5%).12-
15 However, two of these patients showed HPC features
only at relapse and not at initial diagnosis,14,15 and two oth-
ers were of Caribbean and Vietnamese origin.12,16
Comprehensively, the rare cases of HPC-associated IVL
diagnosed outside Japan exhibited clinical features similar
to those displayed by patients with HPC-associated IVL
diagnosed in Japan (J-HPC), i.e., significantly higher rates
of advanced disease, fever, hepato-splenic involvement,
bone marrow infiltration, fatigue, jaundice, dyspnea, ane-
mia, thrombocytopenia, and altered liver function tests. In
contrast, the skin and central nervous system, the most
common sites of disease in the classical form of IVL, were
rarely involved in J-HPC patients. To the best of our
knowledge, there is a single case of cutaneous involve-
ment in J-HPC patients, which was represented by a cuta-
neous lesion on the torso reported as a cutaneous indura-
tion without histological confirmation.17 Our analysis
demonstrates that other characteristics, such as age, gen-
der and rates of lymph-node involvement, peripheral
blood dissemination and increased serum LDH levels,
overlap substantially between classical and HPC-related
forms. Both forms share B-cell immunophenotype in
>97% of cases, in contrast to other non-Hodgkin’s lym-
phomas associated with HPC, which are mostly of T-cell
lineage.18 As reported for other hematologic malignan-
cies,19 the presence of HPC has been proposed as a nega-
tive prognostic factor in IVL patients. Unfortunately, the
comparison of therapeutic outcomes among the studied
subgroups was limited by the fact that data from Asian
patients were collected from case reports written by
physicians with different expertise and specializations,
sometimes with incomplete therapeutic data (complete
therapeutic data for 94% of previously reported J-HPC
patients, 70% of J-IVL patients and 88% of Eastern-IVL
patients) and minimal follow-up. In the largest cumulative
series of Japanese patients with IVL,11 the use of anthracy-
cline-based chemotherapy, the standard strategy against
IVL,11,20 resulted in a 55% complete remission rate and a
median OS of 13 months, which are very similar out-
comes to those of the current series of Western-IVL
patients. In the largest reported series of patients with the
so-called Asian variant of IVL, anthracycline-based
chemotherapy was associated with a complete remission
rate of 53%, and a median OS of 10 months.3 At the time
of analysis, the combination of rituximab and chemother-
apy has been reported to have been used in 15 patients
(six in our series), resulting in complete remission in 11 of
12 evaluable patients, and no relapses at a median follow-
up of 15 months; this combined strategy seems to be
advisable in patients with CD20-positive IVL. Con-
solidation with high-dose chemotherapy supported by
autologous stem cell transplantation may improve current
outcomes,21-23 even among J-HPC patients.9 The applica-
tion of such a strategy is, however, greatly limited by the
high median age and poor PS of IVL patients. Thus, the
identification of reliable high-risk predictors constitutes a
relevant issue in the management of patients with IVL. 
The virtually selective geographical distribution of the
HPC-related form of IVL as well as its differences from the
classical form could have environmental causes. In fact, IVL
occurs in rural areas of Southwestern Japan, where human
T-cell lymphotropic virus type-1 (HTLV-1) is endemic,8
and associations with some helminthic infections have
been proposed in J-HPC patients.24 Associations between
IVL and HTLV-1, Epstein-Barr virus, cytomegalovirus, her-
pes simplex virus, varicella-zoster virus and human herpes
virus-6 have not been detected.25 In conclusion, differ-
ences in clinical features of IVL seem to be correlated to
the concomitant presence of HPC rather than to the geo-
graphical area where the lymphoma is diagnosed. At least
two different clinical forms of IVL seem to exist: a classical
form, which is the most common presentation in Western
countries, with frequent involvement of the skin and cen-
tral nervous system and less common infiltration of
hemolymphoid organs; and a HPC-related form, which is
remarkably more common in Japan, with an almost con-
stant involvement of hemolymphoid organs, higher rates
of advanced disease, fever, respiratory symptoms, ane-
mia, and thrombocytopenia, and virtually always sparing
the skin. Despite these clinico-pathological differences,
patients with both forms have a poor prognosis when
treated with anthracycline-based chemotherapy, and
treatment intensification and the addition of rituximab
appear advisable. Extensive phenotypic and molecular
characterization is needed to test whether these different
clinical forms may also have a different biological back-
grounds, and, therefore, international co-operative studies
are warranted. 
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